Regional differences in relaxation of electric field-stimulated canine airway smooth muscle by verapamil, isoproterenol and prostaglandin E2

D. H. Moore, Peter W. Abel, G. A. Rinard, A. M. Puckett, J. B. Walter

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Regional differences in contraction produced by methacholine and electric field stimulation (EFS) and in relaxation produced by isoproterenol, prostaglandin E2 and verapamil were studied in isolated canine airway smooth muscle in vitro. Low-frequency EFS (3 Hz, 0.5 msec, 50 V) contracted thoracic trachealis to 43% of maximal EFS response, whereas cervical trachealis contracted to only 14% of maximum. EFS at 10 Hz produced 75% of the maximal response in both regions of the trachea. These EFS responses were abolished by 0.1 μM tetrodotoxin and 1.0 μM atropine. Contraction produced by EFS was also matched in each tissue by contraction with methacholine. The concentrations of methacholine that matched EFS at 10 Hz were 52 ± 7, 378 ± 84 and 66 ± 11 nM for cervical and thoracic trachealis and lobar bronchi, respectively. Both EFS and matched methacholine contractions of cervical trachealis and lobar bronchi were completely relaxed by isoproterenol, whereas thoracic trachealis relaxed maximally to only 60% of induced tone. When verapamil was used to relax EFS and matched methacholine contractions, cervical trachealis was completely relaxed whereas thoracic trachealis relaxed to 15% of induced tone. Although there was a regional difference in the relaxant potency of isoproterenol and, to some extent, verapamil, there was no difference in isoproterenol or verapamil EC50 values for EFS vs. matched methacholine contrast within each region. In contrast, EFS contractions of thoracic trachealis were more sensitive to prostaglandin E2-induced relaxation than were matched methacholine contractions. These data demonstrate marked differences in cholinergic and beta adrenergic receptor-mediated responses between regions of the tracheobronchial tree. The authors have also shown that isoproterenol and verapamil relax airways by a direct action on the muscle cells, whereas prostaglandin E2 selectively inhibits EFS-induced contraction in thoracic trachealis.

Original languageEnglish
Pages (from-to)76-82
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume238
Issue number1
StatePublished - 1986
Externally publishedYes

Fingerprint

Verapamil
Isoproterenol
Dinoprostone
Electric Stimulation
Smooth Muscle
Canidae
Methacholine Chloride
Thorax
Bronchi
Receptors, Adrenergic, beta
Tetrodotoxin
Trachea
Atropine
Muscle Cells
Cholinergic Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Regional differences in relaxation of electric field-stimulated canine airway smooth muscle by verapamil, isoproterenol and prostaglandin E2 . / Moore, D. H.; Abel, Peter W.; Rinard, G. A.; Puckett, A. M.; Walter, J. B.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 238, No. 1, 1986, p. 76-82.

Research output: Contribution to journalArticle

@article{8d11039180dc4e7981348dd5ac1e2c58,
title = "Regional differences in relaxation of electric field-stimulated canine airway smooth muscle by verapamil, isoproterenol and prostaglandin E2",
abstract = "Regional differences in contraction produced by methacholine and electric field stimulation (EFS) and in relaxation produced by isoproterenol, prostaglandin E2 and verapamil were studied in isolated canine airway smooth muscle in vitro. Low-frequency EFS (3 Hz, 0.5 msec, 50 V) contracted thoracic trachealis to 43{\%} of maximal EFS response, whereas cervical trachealis contracted to only 14{\%} of maximum. EFS at 10 Hz produced 75{\%} of the maximal response in both regions of the trachea. These EFS responses were abolished by 0.1 μM tetrodotoxin and 1.0 μM atropine. Contraction produced by EFS was also matched in each tissue by contraction with methacholine. The concentrations of methacholine that matched EFS at 10 Hz were 52 ± 7, 378 ± 84 and 66 ± 11 nM for cervical and thoracic trachealis and lobar bronchi, respectively. Both EFS and matched methacholine contractions of cervical trachealis and lobar bronchi were completely relaxed by isoproterenol, whereas thoracic trachealis relaxed maximally to only 60{\%} of induced tone. When verapamil was used to relax EFS and matched methacholine contractions, cervical trachealis was completely relaxed whereas thoracic trachealis relaxed to 15{\%} of induced tone. Although there was a regional difference in the relaxant potency of isoproterenol and, to some extent, verapamil, there was no difference in isoproterenol or verapamil EC50 values for EFS vs. matched methacholine contrast within each region. In contrast, EFS contractions of thoracic trachealis were more sensitive to prostaglandin E2-induced relaxation than were matched methacholine contractions. These data demonstrate marked differences in cholinergic and beta adrenergic receptor-mediated responses between regions of the tracheobronchial tree. The authors have also shown that isoproterenol and verapamil relax airways by a direct action on the muscle cells, whereas prostaglandin E2 selectively inhibits EFS-induced contraction in thoracic trachealis.",
author = "Moore, {D. H.} and Abel, {Peter W.} and Rinard, {G. A.} and Puckett, {A. M.} and Walter, {J. B.}",
year = "1986",
language = "English",
volume = "238",
pages = "76--82",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Regional differences in relaxation of electric field-stimulated canine airway smooth muscle by verapamil, isoproterenol and prostaglandin E2

AU - Moore, D. H.

AU - Abel, Peter W.

AU - Rinard, G. A.

AU - Puckett, A. M.

AU - Walter, J. B.

PY - 1986

Y1 - 1986

N2 - Regional differences in contraction produced by methacholine and electric field stimulation (EFS) and in relaxation produced by isoproterenol, prostaglandin E2 and verapamil were studied in isolated canine airway smooth muscle in vitro. Low-frequency EFS (3 Hz, 0.5 msec, 50 V) contracted thoracic trachealis to 43% of maximal EFS response, whereas cervical trachealis contracted to only 14% of maximum. EFS at 10 Hz produced 75% of the maximal response in both regions of the trachea. These EFS responses were abolished by 0.1 μM tetrodotoxin and 1.0 μM atropine. Contraction produced by EFS was also matched in each tissue by contraction with methacholine. The concentrations of methacholine that matched EFS at 10 Hz were 52 ± 7, 378 ± 84 and 66 ± 11 nM for cervical and thoracic trachealis and lobar bronchi, respectively. Both EFS and matched methacholine contractions of cervical trachealis and lobar bronchi were completely relaxed by isoproterenol, whereas thoracic trachealis relaxed maximally to only 60% of induced tone. When verapamil was used to relax EFS and matched methacholine contractions, cervical trachealis was completely relaxed whereas thoracic trachealis relaxed to 15% of induced tone. Although there was a regional difference in the relaxant potency of isoproterenol and, to some extent, verapamil, there was no difference in isoproterenol or verapamil EC50 values for EFS vs. matched methacholine contrast within each region. In contrast, EFS contractions of thoracic trachealis were more sensitive to prostaglandin E2-induced relaxation than were matched methacholine contractions. These data demonstrate marked differences in cholinergic and beta adrenergic receptor-mediated responses between regions of the tracheobronchial tree. The authors have also shown that isoproterenol and verapamil relax airways by a direct action on the muscle cells, whereas prostaglandin E2 selectively inhibits EFS-induced contraction in thoracic trachealis.

AB - Regional differences in contraction produced by methacholine and electric field stimulation (EFS) and in relaxation produced by isoproterenol, prostaglandin E2 and verapamil were studied in isolated canine airway smooth muscle in vitro. Low-frequency EFS (3 Hz, 0.5 msec, 50 V) contracted thoracic trachealis to 43% of maximal EFS response, whereas cervical trachealis contracted to only 14% of maximum. EFS at 10 Hz produced 75% of the maximal response in both regions of the trachea. These EFS responses were abolished by 0.1 μM tetrodotoxin and 1.0 μM atropine. Contraction produced by EFS was also matched in each tissue by contraction with methacholine. The concentrations of methacholine that matched EFS at 10 Hz were 52 ± 7, 378 ± 84 and 66 ± 11 nM for cervical and thoracic trachealis and lobar bronchi, respectively. Both EFS and matched methacholine contractions of cervical trachealis and lobar bronchi were completely relaxed by isoproterenol, whereas thoracic trachealis relaxed maximally to only 60% of induced tone. When verapamil was used to relax EFS and matched methacholine contractions, cervical trachealis was completely relaxed whereas thoracic trachealis relaxed to 15% of induced tone. Although there was a regional difference in the relaxant potency of isoproterenol and, to some extent, verapamil, there was no difference in isoproterenol or verapamil EC50 values for EFS vs. matched methacholine contrast within each region. In contrast, EFS contractions of thoracic trachealis were more sensitive to prostaglandin E2-induced relaxation than were matched methacholine contractions. These data demonstrate marked differences in cholinergic and beta adrenergic receptor-mediated responses between regions of the tracheobronchial tree. The authors have also shown that isoproterenol and verapamil relax airways by a direct action on the muscle cells, whereas prostaglandin E2 selectively inhibits EFS-induced contraction in thoracic trachealis.

UR - http://www.scopus.com/inward/record.url?scp=0022536759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022536759&partnerID=8YFLogxK

M3 - Article

C2 - 3522858

AN - SCOPUS:0022536759

VL - 238

SP - 76

EP - 82

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -